BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
26 hedge funds and large institutions have $9.23M invested in BRAINSTORM CELL THERAPUTC in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 6 closing their positions.
98% more capital invested
Capital invested by funds: $4.65M → $9.23M (+$4.58M)
0.46% more ownership
Funds ownership: 0.39% → 0.85% (+0.46%)
0% more funds holding
Funds holding: 26 → 26 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.43M |
| 2 |
PA
Perceptive Advisors
New York
|
+$1.64M |
| 3 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$466K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$86K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$72.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$217K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$177K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$71.4K |
| 4 |
GCAC
Guardian Capital Advisors (Canada)
Toronto,
Ontario, Canada
|
-$41K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$30.9K |
BCLI Hedge Fund Activity: Q2 2017 in Review
26 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q2 2017, worth a combined $9.23M — up 98% from $4.65M a quarter earlier.
Fund positioning in BCLI was balanced in Q2 2017: 6 funds opened new positions, 6 closed out, 4 added to existing stakes and 5 trimmed.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $3.43M. The largest seller was Sabby Management, cutting an estimated $217K.
- 26 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $9.23M of BRAINSTORM CELL THERAPUTC stock for Q2 2017, up 98% quarter-over-quarter.
- 6 funds opened new BRAINSTORM CELL THERAPUTC positions in Q2 2017 and 6 closed out, a net change of 0 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q2 2017 was Sphera Funds Management, an estimated $3.43M added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q2 2017 was Sabby Management, an estimated $217K sold.
Based on aggregated 13F filings for Q2 2017.